Division of Hematology and Oncology

July 28, 2022

Study reveals need for matching targeted therapies with EGFR subtypes

A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.

By Tom Wilemon
June 16, 2022

Breast cancer biomarkers of response

Vanderbilt researchers have identified blood-based biomarkers associated with complete responses to neoadjuvant chemotherapy in patients with breast cancer.

By Joshua Baker
May 26, 2022

Conquer Cancer awards given to five hematology-oncology fellows

Five Vanderbilt University Medical Center hematology and oncology fellows will receive awards from Conquer Cancer, the ASCO Foundation, during the 2022 American Society of Clinical Oncology Annual Meeting in Chicago, June 3-7.

By Tom Wilemon
May 6, 2022

Janet Darnell received a lifesaving lung transplant. Five months later she received lifesaving surgery for colon cancer. She calls herself a “walking miracle.”

Without the lung transplant, the cancer may never have been detected.

By Matt Batcheldor
April 25, 2022

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

By Leigh MacMillan
April 21, 2022

Biltibo receives career development award to support hematology research

Vanderbilt’s Eden Biltibo, MD, a clinical fellow in the Division of Hematology and Oncology, has been selected for the 2022 ASH-CIBMTR-ASTCT Career Development Award.

By Tom Wilemon
March 24, 2022

Berlin named interim leader of Hematology and Oncology

Jordan Berlin, MD, has been appointed interim leader of Vanderbilt's Division of Hematology and Oncology in the Department of Medicine.
By Tom Wilemon
March 17, 2022

Ferrell lands Mark Foundation for Cancer Research award

Vanderbilt's Brent Ferrell, MD, is one of the recipients a 2022 Endeavor Award from the The Mark Foundation for Cancer Research.
By Tom Wilemon
March 7, 2022

Study finds World Trade Center responders at higher risk for blood cancer-associated mutations

A study by Vanderbilt and New York City researchers found that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease
By Tom Wilemon
February 17, 2022

Park named director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, deputy director of the Vanderbilt-Ingram Cancer Center, has been named the center’s new director.
By John Howser
February 17, 2022

Grant to support Haake’s research on kidney cancer

Kure It Cancer Research has awarded a $200,000 grant to support kidney cancer research by Vanderbilt's Scott Haake, MD.
By Tom Wilemon
January 25, 2022

Comprehensive framework outlined for addressing early-onset colorectal cancer research

New research from Vanderbilt sets a comprehensive framework for addressing research challenges and patient needs for people under 50 with colorectal cancer.
By Tom Wilemon
December 24, 2021

Study of fully vaccinated patients with cancer who had breakthrough COVID-19 shows 13% mortality rate

New research finds that fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death.
By Tom Wilemon
1 … 3 4 5 6 7 … 15